Ten years have passed since the release of DSM-5, which brought with it some notable changes in diagnostic labels. In this editorial, the impact of labels, and the changes in labels used in child and adolescent psychiatry, are discussed, with examples drawn from autism and schizophrenia. The diagnostic labels that children and adolescents receive feed into their treatment access and future potential but also to their self-identities. Outside of medicine, extensive budgets and time are spent to test how consumers identify with the labels of products. Diagnoses are not commercial products, of course, but the choice of labels used in child and adolescent psychiatry should remain a priority, in light of their impact on translational science, treatment and on individuals, alongside the ever-evolving nature of language itself.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/jcpp.13839 | DOI Listing |
Cell Mol Biol Lett
January 2025
Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Suzhou Key Laboratory of Drug Research for Prevention and Treatment of Hyperlipidemic Diseases, Soochow University, 199 Ren'ai Road, Suzhou, 215123, Jiangsu, China.
Background: The protein cereblon (CRBN) mediates the antileukemia effect of lenalidomide (Len). Len binds to CRBN, recruits IKZF1/IKZF3, and promotes their ubiquitination and degradation, through which Len exhibits its antileukemia and antimyeloma activity. Therefore, the protein level of CRBN might affect the antiproliferative effect of Len.
View Article and Find Full Text PDFAnal Chem
January 2025
School of Chemistry and Chemical Engineering, State Key Laboratory of Digital Medical Engineering, Southeast University, Nanjing 211189, China.
Formamidopyrimidine DNA glycosylase (Fpg) and flap endonuclease 1 (FEN1) are essential to sustaining genomic stability and integrity, while the abnormal activities of Fpg and FEN1 may lead to various diseases and cancers. The development of simple methods for simultaneously monitoring Fpg and FEN1 is highly desirable. Herein, we construct a multiple cyclic ligation-promoted exponential recombinase polymerase amplification (RPA) platform for sensitive and simultaneous monitoring of Fpg and FEN1 in cells and clinical tissues.
View Article and Find Full Text PDFAnal Chim Acta
March 2025
Holosensor Medical Technology Ltd, Room 12, No. 1798, Zhonghuayuan West Road, Yushan Town, Suzhou, 215000, China; Department of Veterinary Medicine, University of Cambridge, Cambridge, UK. Electronic address:
Rapid and sensitive protein detection methods are of benefit to clinical diagnosis, pathological mechanism research, and infection prevention. However, routine protein detection technologies, such as enzyme-linked immunosorbent assay and Western blot, suffer from low sensitivity, poor quantification and labourious operation. Herein, we developed a fully automated protein analysis system to conduct fast protein quantification at the single molecular level.
View Article and Find Full Text PDFBMJ Open
January 2025
Department of Cardiovascular Sciences, University of Leicester and the National Institute for Health Research Leicester Biomedical Research Centre, Glenfield Hospital, Leicester LE3 9QP, UK
Introduction: Heart failure with preserved ejection fraction (HFpEF) is characterised by severe exercise intolerance, particularly in those living with obesity. Low-energy meal-replacement plans (MRPs) have shown significant weight loss and potential cardiac remodelling benefits. This pragmatic randomised trial aims to evaluate the efficacy of MRP-directed weight loss on exercise intolerance, symptoms, quality of life and cardiovascular remodelling in a multiethnic cohort with obesity and HFpEF.
View Article and Find Full Text PDFJ Ayurveda Integr Med
January 2025
Center for Clinical Research and Education, The University of Trans-Disciplinary Health Sciences and Technology, Bangalore, India; Internal Medicine - Cardiology, University of Michigan, Ann Arbor, MI, USA. Electronic address:
Background: Obesity is a rising risk factor for various diseases including cardiovascular diseases and Cancer. The limitations of targeted obesity-treatment approaches employed in the clinic presently underscore the importance of developing integrative management strategies for identification of specific biomarkers of obesity.
Objectives: Given the specificity of exosome/extracellular vesicle (EV) biomarkers, we aimed here to identify the EV biomarkers of Ayurveda treatment - Lekhana Basti - for Obesity.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!